• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有脂肪性肝病和乙型肝炎病毒的肝细胞癌患者中,根据总肿瘤体积或肿瘤负荷评分预测的生存率比较。

Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus.

作者信息

Li Min-Jun, Xie Si, Teng Yu-Xian, Ma Liang, Li Le-Qun, Xiang Bang-De, Zhong Jian-Hong

机构信息

Hepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Guangxi Medical University Cancer Hospital, Nanning, China.

Ministry of Education; Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Nanning, China.

出版信息

Expert Rev Gastroenterol Hepatol. 2023 May;17(5):499-507. doi: 10.1080/17474124.2023.2196403. Epub 2023 Apr 3.

DOI:10.1080/17474124.2023.2196403
PMID:36975382
Abstract

OBJECTIVES

To analyze prognostic value of total tumor volume (TTV) and tumor burden score (TBS) in surgically treated patients with hepatocellular carcinoma and concurrent fatty liver disease and hepatitis B virus (FLD-HCC).

METHODS

FLD-HCC patients who treated with hepatectomy from 2010 to 2018 were analyzed. Prognostic performance of TTV and TBS was determined by ROC analysis. Patients were stratified into low and high tumor burden by optimal cutoff value of 113.4 cm for TTV or 6.3 points for TBS. Survival rates were compared between subgroups and independent risk factors were identified by Cox regression. Correlation between TTV and TBS was evaluated.

RESULTS

This study enrolled 342 FLD-HCC patients. Survival was significantly higher among patients with low tumor burden than among those with high tumor burden ( < 0.001). High TTV and TBS were independent risk factors for poor survival of FLD-HCC (HR: 3.27 (2.17-4.93) and 3.48 (2.31-5.26), respectively, all  < 0.001). ROC analyses revealed that TTV and TBS had comparable discriminative ability in stratifying overall and recurrence-free survival of FLD-HCC. Correlation analysis revealed a strong correlation between TTV and TBS.

CONCLUSIONS

Both TTV and TBS have comparable prognostic value and high TTV/TBS predicts poor survival of patients with FLD-HCC.

摘要

目的

分析总肿瘤体积(TTV)和肿瘤负荷评分(TBS)在接受手术治疗的肝细胞癌合并脂肪性肝病和乙型肝炎病毒(FLD-HCC)患者中的预后价值。

方法

分析2010年至2018年接受肝切除术的FLD-HCC患者。通过ROC分析确定TTV和TBS的预后性能。根据TTV的最佳截断值113.4 cm或TBS的6.3分将患者分为低肿瘤负荷和高肿瘤负荷组。比较亚组之间的生存率,并通过Cox回归确定独立危险因素。评估TTV和TBS之间的相关性。

结果

本研究纳入了342例FLD-HCC患者。低肿瘤负荷患者的生存率显著高于高肿瘤负荷患者(<0.001)。高TTV和TBS是FLD-HCC患者生存不良的独立危险因素(HR分别为3.27(2.17-4.93)和3.48(2.31-5.26),均<0.001)。ROC分析显示,TTV和TBS在分层FLD-HCC患者的总生存和无复发生存方面具有相当的判别能力。相关性分析显示TTV和TBS之间存在强相关性。

结论

TTV和TBS具有相当的预后价值,高TTV/TBS预示着FLD-HCC患者生存不良。

相似文献

1
Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus.伴有脂肪性肝病和乙型肝炎病毒的肝细胞癌患者中,根据总肿瘤体积或肿瘤负荷评分预测的生存率比较。
Expert Rev Gastroenterol Hepatol. 2023 May;17(5):499-507. doi: 10.1080/17474124.2023.2196403. Epub 2023 Apr 3.
2
Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma.肿瘤总体积可预测肝细胞癌患者肝切除术后的生存率。
Tumour Biol. 2016 Jul;37(7):9301-10. doi: 10.1007/s13277-016-4794-7. Epub 2016 Jan 15.
3
The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.术前甲胎蛋白水平与肿瘤总体积比值作为肝移植后肝细胞癌的预后因素。
Medicine (Baltimore). 2021 Jul 2;100(26):e26487. doi: 10.1097/MD.0000000000026487.
4
Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria.肿瘤总体积是米兰标准定义的肝细胞癌肿瘤负荷的更好标志物。
World J Surg. 2013 Jun;37(6):1348-55. doi: 10.1007/s00268-013-1978-9.
5
Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.总体肿瘤负担决定了米兰标准以外的多结节性肝细胞癌患者切除术后的结局。
Ann Surg. 2020 Oct;272(4):574-581. doi: 10.1097/SLA.0000000000004346.
6
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.基于总肿瘤体积的肝细胞癌新预后模型:台北综合评分系统。
J Hepatol. 2010 Jul;53(1):108-17. doi: 10.1016/j.jhep.2010.01.038. Epub 2010 Mar 31.
7
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.肿瘤负担评分对肝癌患者预后分层的效用:ITA.LI.CA 研究组 4759 例患者的结果。
J Gastrointest Surg. 2018 May;22(5):859-871. doi: 10.1007/s11605-018-3688-y. Epub 2018 Jan 19.
8
Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.经导管动脉化疗栓塞术对肝细胞癌术后辅助治疗的临床疗效
World J Surg Oncol. 2016 Apr 2;14:100. doi: 10.1186/s12957-016-0855-z.
9
A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection.一种新的基于炎症指标和肿瘤负荷评分(TBS)的模型,用于预测肝癌(HCC)肝切除术后的复发。
Sci Rep. 2022 May 23;12(1):8670. doi: 10.1038/s41598-022-12518-5.
10
Poor association of TT virus viremia with hepatocellular carcinoma.TT病毒血症与肝细胞癌的关联性较弱。
Liver. 2000 Jun;20(3):247-52. doi: 10.1034/j.1600-0676.2000.020003247.x.

引用本文的文献

1
A preoperative inflammatory score-based nomogram predicts overall survival after curative hepatectomy for hepatocellular carcinoma.基于术前炎症评分的列线图可预测肝细胞癌根治性肝切除术后的总生存期。
Discov Oncol. 2025 Aug 31;16(1):1659. doi: 10.1007/s12672-025-03406-1.
2
High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.高肿瘤负荷评分提示肝细胞癌患者预后不良:一项荟萃分析。
PLoS One. 2024 Aug 8;19(8):e0308570. doi: 10.1371/journal.pone.0308570. eCollection 2024.
3
Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.
肝细胞癌根治性治疗后的辅助治疗:几个未解决的问题。
J Clin Transl Hepatol. 2024 May 28;12(5):525-533. doi: 10.14218/JCTH.2024.00030. Epub 2024 Apr 24.
4
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.辅助免疫检查点抑制剂与术后肝细胞癌(PREVENT)无复发生存率的提高相关:一项前瞻性、多中心队列研究。
J Gastroenterol. 2023 Oct;58(10):1043-1054. doi: 10.1007/s00535-023-02018-2. Epub 2023 Jul 14.